Related Experiment Video

Updated: May 26, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Forty-year journey of angiogenesis translational research

Yihai Cao1, Jack Arbiser, Robert J D'Amato

  • 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden. yihai.cao@ki.se

Science Translational Medicine
|December 23, 2011
PubMed

Insights

Forty years of angiogenesis research show tumor growth depends on new blood vessel formation. Inhibiting this process, known as antiangiogenic therapy, is now used to treat cancers and eye diseases.

Area of Science:

  • Oncology
  • Vascular Biology
  • Translational Medicine

Background:

  • Judah Folkman's hypothesis: tumor growth requires angiogenesis.
  • Angiogenesis research has led to new cancer and retinal disease therapies.
  • Antiangiogenic drugs are now clinically utilized.

Purpose of the Study:

  • Review 40 years of angiogenesis research.
  • Discuss the clinical translation of antiangiogenic strategies.
  • Identify challenges in current antiangiogenic therapy.

Main Methods:

  • Literature review of angiogenesis research.
  • Analysis of clinical applications of antiangiogenic drugs.
  • Discussion of therapeutic challenges and future directions.

Main Results:

  • Folkman's hypothesis spurred a new field of cancer research.
  • Antiangiogenic therapies are effective for cancers and retinal vascular diseases.
  • Significant progress has been made in understanding and targeting angiogenesis.

Conclusions:

  • Angiogenesis inhibition is a validated therapeutic strategy.
  • Translating basic science discoveries into patient benefits is demonstrated.
  • Overcoming challenges in antiangiogenic therapy is crucial for future success.

More Related Videos

Investigating Angiogenesis on a Functional and Molecular Level by Leveraging the Scratch Wound Migration Assay and the Spheroid Sprouting Assay09:16

Investigating Angiogenesis on a Functional and Molecular Level by Leveraging the Scratch Wound Migration Assay and the Spheroid Sprouting Assay

Published on: May 31, 2024

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...